Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Extravascular Hemolysis”

8 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 8 of 8 results

Large-scale testing (Phase 3)Study completedNCT04469465
What this trial is testing

Danicopan as Add-on Therapy to a C5 Inhibitor in Paroxysmal Nocturnal Hemoglobinuria (PNH) Participants Who Have Clinically Evident Extravascular Hemolysis (EVH)(ALPHA)

Who this might be right for
Paroxysmal Nocturnal Hemoglobinuria
Alexion Pharmaceuticals, Inc. 86
Testing effectiveness (Phase 2)Ended earlyNCT04170023
What this trial is testing

Study of the Oral Factor D (FD) Inhibitor ALXN2050 in PNH Patients as Monotherapy

Who this might be right for
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Alexion Pharmaceuticals, Inc. 29
Early research (Phase 1)Study completedNCT02588833
What this trial is testing

Pilot Study to Assess Safety, Preliminary Efficacy and Pharmacokinetics of S.C. Pegcetacoplan (APL-2) in PNH Subjects.

Who this might be right for
Paroxysmal Nocturnal Hemoglobinuria
Apellis Pharmaceuticals, Inc. 23
Large-scale testing (Phase 3)Active Not RecruitingNCT05389449
What this trial is testing

A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNH

Who this might be right for
Paroxysmal Nocturnal Hemoglobinuria
Alexion Pharmaceuticals, Inc. 80
Testing effectiveness (Phase 2)Study completedNCT03593200
What this trial is testing

A Phase IIa Study to Assess the Safety, Efficacy, and Pharmacokinetics of Subcutaneously Administered Pegcetacoplan (APL-2) in Subjects With PNH

Who this might be right for
PNH
Apellis Pharmaceuticals, Inc. 4
Early research (Phase 1)Study completedNCT02264639
What this trial is testing

A Phase I Study to Assess the Safety of Pegcetacoplan (APL-2) as an Add-On to Standard of Care in Subjects With PNH

Who this might be right for
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Apellis Pharmaceuticals, Inc. 9
Large-scale testing (Phase 3)Looking for participantsNCT06449001
What this trial is testing

Study of Danicopan as Add-on Treatment to Ravulizumab or Eculizumab in Pediatric Participants With PNH Who Have Clinically Significant Extravascular Hemolysis

Who this might be right for
Paroxysmal Nocturnal HemoglobinuriaPNHExtravascular Hemolysis
Alexion Pharmaceuticals, Inc. 6
Not applicableAvailableNCT05982938
What this trial is testing

Danicopan Early Access Program

Who this might be right for
Paroxysmal Nocturnal HemoglobinuriaPNHExtravascular Hemolysis
Alexion Pharmaceuticals, Inc.